Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Robert M. Langdon"'
Autor:
Kevin P. Becker, John D. Hainsworth, Tarek Mekhail, David Wright, Howard A. Burris, Sajeel A. Chowdhary, Janice Faulkner Eakle, Kimberly West-Osterfield, Gilbert Darin Anthony Padula, Mythili Shastry, Meredith Scarberry, Kent C. Shih, Robert M. Langdon, Candice A. Shaifer, Kathleen Yost
Publikováno v:
Journal of Neuro-Oncology. 144:303-311
Current bevacizumab-based regimens have failed to improve survival in patients with recurrent glioblastoma. To improve treatment efficacy, we evaluated bevacizumab + BKM120, an oral pan-class I PI3K inhibitor, in this patient population. A brief phas
Autor:
Bamidele A. Adesunloye, Ebenezer A. Kio, Shadia I. Jalal, Karen L. Reckamp, Michael L. Titzer, Robert M. Langdon, Robin Zon, Greg Andrew Durm, Goetz H. Kloecker, Sandra Althouse, Wael A. Harb, Ryan D. Gentzler, Radhika V. Walling, Ziyue Liu, Nasser H. Hanna, Salma K. Jabbour, Michael J. Williamson, Ahad Ali Sadiq
Publikováno v:
CancerReferences. 126(19)
BACKGROUND Five-year overall survival (OS) for patients with unresectable stage III non-small cell lung cancer (NSCLC) is poor. Until recently, a standard of care was concurrent chemoradiation alone. Patients with metastatic NSCLC treated with anti-p
Autor:
Peter Paul Yu, Patricia A. Ganz, J. Russell Hoverman, Dana S. Wollins, Julie M. Vose, Thomas J. Smith, Gary H. Lyman, Gregory Rossi, Douglas W. Blayney, Robert M. Langdon, Leonard B. Saltz, Deborah Schrag, Derek Raghavan, Richard L. Schilsky, Lowell E. Schnipper, Therese M. Mulvey, Lee N. Newcomer, Nancy E. Davidson, Blase N. Polite, Jeffrey Peppercorn, Adam P. Dicker, Neal J. Meropol, Clifford A. Hudis
Publikováno v:
Journal of Clinical Oncology. 34:2925-2934
The mission of American Society of Clinical Oncology (ASCO) is to conquer cancer through research, education, and promotion of the highest quality patient care. Toward fulfillment of this goal and at the direction of its board of directors, the ASCOV
Autor:
Mikhail V. Kopp, Aleksey Severtsev, Alberto Bessudo, Ching Hsu, Oleg Gladkov, Sandro Barni, Lothar Müller, Vladimir Ivanovich Vladimirov, Lowell L. Hart, Johanna C. Bendell, Ellen Bolotin, Brian Schwartz, Bogdan Kotiv, Reinhard von Roemeling, Cathy Eng, Robert M. Langdon
Publikováno v:
International Journal of Cancer
Cetuximab in combination with an irinotecan‐containing regimen is a standard treatment in patients with KRAS wild‐type (KRAS WT), metastatic colorectal cancer (mCRC). We investigated the addition of the oral MET inhibitor tivantinib to cetuximab
Autor:
Wael A. Harb, Julie M. Vose, Sharon Horton, Leo I. Gordon, Thorsten Graef, Andrew M. Evens, Sriram Balasubramanian, Nancy L. Bartlett, Julian Sprague, Robert M. Langdon, Chitra Mani, Mint Sirisawad, Ying Luan, Jeanne Yue
Publikováno v:
Clinical Cancer Research. 22:1059-1066
Purpose: Additional targeted therapeutics are needed for the treatment of lymphoma. Abexinostat is an oral pan-histone deacetylase inhibitor (HDACi) displaying potent activity in preclinical models. We conducted a multicenter phase I/II study (N = 55
Autor:
Ryan D. Gentzler, Ahad Ali Sadiq, Goetz H. Kloecker, Robert M. Langdon, Shadia I. Jalal, Karen L. Reckamp, Sandra K. Althouse, Greg Andrew Durm, Salma K. Jabbour, Nikhil Shukla, Nasser H. Hanna, Bamidele Adesunloye, Robin Zon, William B. Fisher, Ebenezer A. Kio
Publikováno v:
Journal of Clinical Oncology. 38:9032-9032
9032 Background: Consolidation checkpoint inhibitor therapy (CPI) for up to 1 year following chemoradiation (CRT) is a current standard of care for pts with inoperable stage III NSCLC. However, some pts are not able to complete 1 year of CPI due to i
Autor:
Peter Paul Yu, Deborah Schrag, Lowell E. Schnipper, Blase N. Polite, Diane Blum, Leonard B. Saltz, Therese M. Mulvey, J. Russell Hoverman, Adam P. Dicker, Lee N. Newcomer, Patricia A. Ganz, Derek Raghavan, Gregory Rossi, Thomas J. Smith, Nancy E. Davidson, Neal J. Meropol, Dana S. Wollins, Richard L. Schilsky, Clifford A. Hudis, Douglas W. Blayney, Courtney Tyne, Gary H. Lyman, Jeffrey Peppercorn, Robert M. Langdon
Publikováno v:
Journal of Clinical Oncology. 33:2563-2577
Health care costs in the United States present a major challenge to the national economic well being. The Centers for Medicare and Medicaid Services (CMS) has projected that US health care spending will reach $4.3 trillion and account for 19.3% of th
Autor:
Robin Zon, Ebenezer A. Kio, Karen L. Reckamp, Goetz H. Kloecker, Nasser H. Hanna, Sandra K. Althouse, M. Williamson, C. Yeon, B. Adesunloye, Salma K. Jabbour, G. Durm, Ryan D. Gentzler, Shadia I. Jalal, Wael A. Harb, Marianna Koczywas, Radhika Walling, Robert M. Langdon, Ahad Ali Sadiq
Publikováno v:
Journal of Thoracic Oncology. 14:S627
Autor:
Ebenezer A. Kio, Ahad Ali Sadiq, Robin Zon, B. Adesunloye, Ryan D. Gentzler, Shadia I. Jalal, Salma K. Jabbour, G. Durm, Robert M. Langdon, William B. Fisher, Karen L. Reckamp, Sandra Althouse, Nasser H. Hanna, Goetz H. Kloecker
Publikováno v:
Journal of Thoracic Oncology. 13:S321
Autor:
William B. Fisher, Robert M. Langdon, Ahad Ali Sadiq, Robin Zon, Goetz H. Kloecker, Ryan D. Gentzler, Ebenezer A. Kio, Shadia I. Jalal, Bamidele Adesunloye, Karen L. Reckamp, Salma K. Jabbour, Greg Andrew Durm, Sandra K. Althouse, Nasser H. Hanna
Publikováno v:
Journal of Clinical Oncology. 36:8500-8500
8500Background: Concurrent chemoradiation (CRT) has been the standard Rx for pts with unresectable stage III NSCLC. A recent phase III trial (PACIFIC) of consolidation durvalumab [PDL-1 inhibitor] ...